

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## 144: Filer Information

Filer CIK 0001968251  
Filer CCC XXXXXXXXX  
Is this a LIVE or TEST Filing?  LIVE  TEST

### Submission Contact Information

Name  
Phone  
E-Mail Address

## 144: Issuer Information

Name of Issuer Apollomics Inc.  
SEC File Number 001-41670  
Address of Issuer 989 E. Hillsdale Blvd.  
Suite 220  
Foster City  
CALIFORNIA  
94404  
Phone 650-209-4055  
Name of Person for Whose Account the Securities are To Be Sold OrbiMed Asia Partners II, L.P.  
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.  
Relationship to Issuer Shareholder

## 144: Securities Information

| Title of the Class of Securities To Be Sold | Name and Address of the Broker                       | Number of Shares or Other Units To Be Sold | Aggregate Market Value | Number of Shares or Other Units Outstanding | Approximate Date of Sale | Name the Securities Exchange |
|---|--|--|------------------------|---|--------------------------|------------------------------|
| Class A Ordinary Shares                     | Morgan Stanley<br>1585 Broadway<br>New York NY 10036 | 9515756                                    | 11323750.00            | 89480790                                    | 11/27/2023               | Nasdaq Stock Market          |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

| Title of the Class | Date you Acquired | Nature of Acquisition Transaction | Name of Person from | Is this | Date Donor Acquired | Amount of Securities Acquired | Date of Payment | Nature of Payment * |
|--------------------|-------------------|-----------------------------------|---------------------|---------|---------------------|-------------------------------|-----------------|---------------------|
|--------------------|-------------------|-----------------------------------|---------------------|---------|---------------------|-------------------------------|-----------------|---------------------|

|                            |            |                         |                          |                          |         |                 |
|----------------------------|------------|-------------------------|--------------------------|--------------------------|---------|-----------------|
|                            |            |                         | <b>Whom<br/>Acquired</b> | <b>a<br/>Gift?</b>       |         |                 |
| Class A<br>ordinary shares | 03/29/2023 | Business<br>combination | Issuer                   | <input type="checkbox"/> | 9515756 | 03/29/2023 Cash |

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

| Name and Address of Seller  | Title of Securities Sold | Date of Sale | Amount of Securities Sold | Gross Proceeds |
|---|--------------------------|--------------|---------------------------|----------------|
| OrbiMed Asia GP II, L.P.<br>601 Lexington Ave.<br>54th Floor<br>New York NY 10022 | Class A ordinary shares  | 11/16/2023   | 6700000                   | 8375000.00     |

## 144: Remarks and Signature

Remarks OrbiMed Asia GP II, L.P. is the general partner of OrbiMed Asia Partners II, L.P., and OrbiMed Advisors II Limited is the general partner of OrbiMed Asia GP II, L.P. OrbiMed Advisors LLC is the advisory company of OrbiMed Asia Partners II, L.P.

Date of Notice 11/27/2023

**ATTENTION:**

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors II Limited, general partner of the general partner of OrbiMed Asia Partners II, L.P.

**ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)**